Q1 Financial Results & Business Updates Listen to the replay Latest News May 28, 2020 Abeona Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference View Press Release May 6, 2020 Abeona Therapeutics Reports First Quarter Financial Results and Business Updates View Press Release Apr 21, 2020 Abeona Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) View Press Release View All Our inspiration Learn More Pipeline Our clinical-stage therapies are designed to deliver functional copies of affected genes to cells using gene transfer technologies. Explore R&D EB-101 In Phase 3 development. Autologous gene-corrected cell therapy for patients with RDEB. Learn More ABO-102 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA). Learn More ABO-101 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type B (MPS IIIB). Learn More Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
